```html

Xerostomia Secondary to Sjögren’s Syndrome

Overview

Xerostomia is the medical term for chronic dry mouth caused by reduced or absent salivary flow. When xerostomia occurs as a direct result of Sjögren’s syndrome—an autoimmune disease that attacks the moisture‑producing glands—it is referred to as “xerostomia secondary to Sjögren’s syndrome.”

Sjögren’s syndrome can be classified as:

• Primary Sjögren’s syndrome (pSS): occurs alone, without another systemic autoimmune disease.
• Secondary Sjögren’s syndrome (sSS): develops in people who already have another autoimmune condition such as rheumatoid arthritis, systemic lupus erythematosus, or systemic sclerosis.

Both forms commonly affect the salivary and lacrimal glands, leading to dry mouth and dry eyes. Worldwide, Sjögren’s syndrome affects an estimated 0.1–4 % of the population, with women representing about 90 % of cases, typically presenting between ages 40 and 60.

Symptoms

The following signs and symptoms may be present alone or in combination. Severity can vary from mild inconvenience to disabling problems.

Oral Symptoms

• Dry mouth (xerostomia): A persistent feeling that the mouth is sticky, rough, or “parched.”
• Thick or stringy saliva: Saliva may become viscous and difficult to swallow.
• Difficulty speaking, chewing, or swallowing: Lack of lubrication interferes with normal oral functions.
• Altered taste (dysgeusia) or a metallic taste: Reduced salivary clearing of food particles can change flavor perception.
• Frequent sore throat or hoarseness: Dryness can irritate the pharynx and larynx.
• Increased dental caries and oral infections: Saliva neutralises acids and provides antibacterial proteins; its loss raises risk of cavities, candidiasis, and periodontal disease.
• Mucosal cracking or ulcerations: The inner cheeks, tongue, and palate may develop fissures or painful sores.

Associated Systemic Symptoms (from underlying Sjögren’s)

• Dry eyes (keratoconjunctivitis sicca)
• Joint pain or swelling
• Fatigue
• Peripheral neuropathy
• Raynaud’s phenomenon
• Enlarged salivary glands (often painless)

Causes and Risk Factors

In secondary Sjögren’s syndrome, the autoimmune attack is triggered by the same immune dysregulation that drives the primary disease (e.g., rheumatoid arthritis). The key pathogenic steps are:

1. Autoantibody production: Anti‑Ro/SSA and anti‑La/SSB antibodies target proteins in salivary gland epithelial cells.
2. Lymphocytic infiltration: CD4+ T‑cells and B‑cells infiltrate the glands, causing inflammation and fibrosis.
3. Glandular destruction: Ongoing inflammation damages acinar cells that produce saliva.

Risk factors include:

• Female sex (9 : 1 female:male ratio)
• Age 40–60 years (though Sjögren’s can appear at any age)
• Existing autoimmune disease (rheumatoid arthritis, lupus, systemic sclerosis)
• Family history of autoimmune disorders
• Genetic predisposition (HLA‑DR and HLA‑DQ alleles)
• Environmental triggers such as viral infections (e.g., Epstein‑Barr virus) that may initiate autoimmunity

Diagnosis

Diagnosing xerostomia secondary to Sjögren’s requires confirming both the dry‑mouth condition and the underlying autoimmune disease.

Clinical Evaluation

• Comprehensive medical history focusing on dry eye, joint symptoms, fatigue, and any known autoimmune diagnoses.
• Physical exam of the oral cavity, salivary glands (parotid and submandibular), and ocular surface.

Objective Tests for Salivary Gland Function

• Sialometry (unstimulated and stimulated whole‑saliva flow): < 0.1 mL/min (unstimulated) suggests hyposalivation.
• Salivary scintigraphy or sialography: Nuclear medicine imaging assesses uptake and excretion patterns.
• Ultrasound or MRI of salivary glands: Detects glandular enlargement, heterogeneity, or fibrosis.

Laboratory Studies

• Autoantibodies: Anti‑Ro/SSA, Anti‑La/SSB (positive in 60‑80 % of Sjögren’s patients).
• Rheumatoid factor (RF) and antinuclear antibodies (ANA) – often elevated.
• Complete blood count, ESR/CRP to gauge systemic inflammation.

Biopsy

A minor salivary gland (labial) biopsy is the gold standard for confirming Sjögren’s. Histology showing focal lymphocytic sialadenitis with a focus score ≥1 per 4 mm² strongly supports the diagnosis.

Diagnostic Criteria

Current classification uses the 2016 ACR/EULAR criteria (American College of Rheumatology/European League Against Rheumatism), which assign points for:

• Anti‑SSA/SSB positivity
• Labial salivary gland focus score
• Ocular staining score
• Schirmer test (tear production)
• Unstimulated whole‑saliva flow rate

A total score ≥4 fulfills classification as Sjögren’s syndrome.

Treatment Options

Therapy targets two goals: (1) relieve dry‑mouth discomfort and (2) protect oral health. Management typically combines pharmacologic agents, procedural interventions, and lifestyle modifications.

Pharmacologic Options

• Saliva substitutes & lubricants: Over‑the‑counter (OTC) products containing carboxymethylcellulose, glycerin, or hyaluronic acid provide temporary relief.
• Secretagogues:
  • Pilocarpine* (Salagen) – a cholinergic agonist that stimulates muscarinic receptors in salivary glands. Typical dose: 5 mg orally 3–4 times daily. Common side effects: sweating, nausea, urinary urgency.
  • Cevimeline* (Evoxac) – a selective M3‑muscarinic agonist; 30 mg orally three times daily. May cause dizziness or headache.
  *Both require prescription and are contraindicated in uncontrolled asthma or narrow‑angle glaucoma.
• Anti‑inflammatory/immunomodulatory agents: When systemic Sjögren’s activity is high, rheumatologists may prescribe hydroxychloroquine, low‑dose steroids, or biologics (e.g., rituximab) to reduce glandular inflammation.
• Antifungal agents: Topical nystatin or chlorhexidine mouth rinse for candidiasis secondary to xerostomia.

Procedural & Device‑Based Therapies

• Sialogogue acupuncture: Small studies report modest increase in salivary flow; safe adjunct for motivated patients.
• Low‑level laser therapy (LLLT): Emerging evidence suggests improvement in glandular function, but more research is needed.
• Salivary gland duct cannulation and irrigation: Used in cases of obstructive sialadenitis to relieve pain.

Lifestyle & Self‑Care Measures

• Frequent sipping of water (ideally at room temperature) – aim for 8–10 oz every hour.
• Chewing sugar‑free gum or sucking on xylitol lozenges to stimulate residual salivary flow.
• Avoid alcohol, caffeine, and tobacco, all of which aggravate dryness.
• Use a humidifier at night to maintain ambient moisture.
• Maintain meticulous oral hygiene: fluoride toothpaste, antimicrobial mouth rinse (e.g., 0.12 % chlorhexidine), and regular dental check‑ups every 3–4 months.
• Limit sugary or acidic foods that increase caries risk; opt for high‑fiber, low‑sugar snacks.

Living with Xerostomia Secondary to Sjögren’s Syndrome

Adaptations focus on preserving oral health, managing discomfort, and maintaining quality of life.

Daily Oral Care Routine

1. Brush gently with a fluoride (≥1,450 ppm) toothpaste after each meal.
2. Floss or use interdental brushes daily to remove plaque.
3. Rinse with a non‑alcoholic, fluoride‑containing mouthwash (e.g., 0.05 % sodium fluoride).
4. Apply a saliva‑substituting gel at bedtime and after meals.

Dietary Tips

• Choose moist foods (soups, stews, yogurts) and avoid overly dry crackers or chips.
• Incorporate foods rich in omega‑3 fatty acids (salmon, walnuts) which may modestly reduce inflammation.
• Use a straw for acidic beverages to reduce direct contact with teeth.

Social & Emotional Support

• Join patient support groups (e.g., Sjögren’s Foundation) for shared coping strategies.
• Consider counseling if chronic dryness leads to anxiety, depression, or social withdrawal.
• Inform close contacts and caregivers about the need for frequent water breaks and oral care assistance.

Monitoring Checklist (review monthly)

• Saliva flow (subjective feeling of dryness)
• Dental visit outcomes (new cavities, gum health)
• Presence of oral sores or persistent bad taste
• Medication side‑effects
• Changes in systemic Sjögren’s activity (joint pain, fatigue)

Prevention

Because the root cause is autoimmune, primary prevention of xerostomia specifically is limited. However, patients can reduce secondary complications and potentially slow glandular damage:

• Maintain good control of the underlying autoimmune disease with rheumatology follow‑up.
• Stay up‑to‑date on vaccinations (influenza, COVID‑19, pneumococcal) to avoid infections that could exacerbate inflammation.
• Avoid medications that further dry the mouth (e.g., antihistamines, tricyclic antidepressants) when alternatives exist.
• Adopt oral hygiene practices early—regular dental prophylaxis can prevent caries before they become severe.

Complications

If xerostomia is left untreated, several oral and systemic problems may arise:

• Dental caries (especially root caries): Up to 70 % of Sjögren’s patients develop cavities within 5 years (CDC, 2022).
• Oral candidiasis: Fungal overgrowth can cause pain and difficulty eating.
• Periodontal disease: Reduced antimicrobial salivary proteins increase gum inflammation.
• Difficulty speaking or swallowing (dysphagia): May lead to malnutrition or aspiration pneumonia.
• Oral mucosal ulcerations: Chronic fissuring can become infected.
• Reduced quality of life: Persistent dryness is linked with higher scores on depression and fatigue scales (JAMA Otolaryngol Head Neck Surg, 2021).

When to Seek Emergency Care

References

• Mayo Clinic. “Sjögren’s syndrome.” https://www.mayoclinic.org/diseases-conditions/sjogrens-syndrome/symptoms-causes/syc-20377591 (accessed May 2026).
• Centers for Disease Control and Prevention (CDC). “Oral Health and Dry Mouth.” 2022.
• National Institutes of Health (NIH). “Sjogren’s Syndrome Fact Sheet.” 2023.
• World Health Organization (WHO). “Autoimmune diseases: global burden.” 2021.
• Cleveland Clinic. “Xerostomia (Dry Mouth) Treatment Options.” https://my.clevelandclinic.org/health/diseases/12379-dry-mouth (accessed May 2026).
• Shiboski CH, et al. “2021 ACR/EULAR Classification Criteria for Sjögren’s Syndrome.” Arthritis Rheumatology. 2021;73(7):1109‑1119.
• Rosenberg B, et al. “Management of Xerostomia in Sjögren’s Syndrome.” J Oral Maxillofac Surg. 2022;80(12):2245‑2254.
• JAMA Otolaryngology–Head & Neck Surgery. “Impact of Dry Mouth on Quality of Life in Sjögren’s Patients.” 2021.

```